BRPI0714667A8 - Conjugado molecular e respectivo uso - Google Patents
Conjugado molecular e respectivo usoInfo
- Publication number
- BRPI0714667A8 BRPI0714667A8 BRPI0714667A BRPI0714667A BRPI0714667A8 BR PI0714667 A8 BRPI0714667 A8 BR PI0714667A8 BR PI0714667 A BRPI0714667 A BR PI0714667A BR PI0714667 A BRPI0714667 A BR PI0714667A BR PI0714667 A8 BRPI0714667 A8 BR PI0714667A8
- Authority
- BR
- Brazil
- Prior art keywords
- photosensitizer
- vector
- conjugates
- ethylene glycol
- glycol units
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
CONJUGADO MOLECULAR E RESPECTIVO USO. São proporcionados conjugados moleculares antimicrobianos para o tratamento e prevenção de doenças infecciosas causadas por microorganismos patogênicos em pessoas humanas e animais. A chave para estes conjugados é um espaçador especial que conecta pelo menos um fotossensibilizador a um receptor de microorganismo(vetor) que, por sua vez, se liga seletivamente à superfície de um microorganismo provocando a fotodestruição por irradiação. Os espaçadores de estrutura hidrofílica tal como unidades de etilenoglicol e unidades de etilenoglicol revestidas no término por amino carboxil devem ser usados para ligar o vetor ao fotossensibilizador. Numa modalidade preferida, um espaçador teria pelo menos 3 unidades de etilenoglicol e seria revestido no término com um grupo carboxil e um grupo amino no outro término. A presente invenção funciona efetivamente para combater a infecção bacteriana nos ambientes reais relacionados com pacientes em que o sangue, soro e outros fluidos de corpo estão sempre presentes ou pelo menos na vizinhança. Os espaçadores de comprimento e estrutura selecionados, em modalidades preferidas, são usados para ligar o vetor ao fotossensibilizador. Estes conjugados são constatados serem muito efetivos no combate à infecção bacteriana nos ambientes reais relacionados com pacientes em que o sangue, o soro e outros fluidos de corpo estão sempre presentes ou pelo menos na vizinhança. É também proporcionado um método de uso.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83383606P | 2006-07-27 | 2006-07-27 | |
US60833,836 | 2006-07-27 | ||
US11/880,974 US20090030257A1 (en) | 2007-07-25 | 2007-07-25 | Anti-microbial photodynamic therapy |
US11880974 | 2007-07-25 | ||
PCT/US2007/016951 WO2009014524A2 (en) | 2006-07-27 | 2007-07-27 | Anti-microbial photodynamic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0714667A2 BRPI0714667A2 (pt) | 2013-08-06 |
BRPI0714667A8 true BRPI0714667A8 (pt) | 2016-10-18 |
Family
ID=40282008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0714667A BRPI0714667A8 (pt) | 2006-07-27 | 2007-07-27 | Conjugado molecular e respectivo uso |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2049105A4 (pt) |
BR (1) | BRPI0714667A8 (pt) |
MX (1) | MX2009001074A (pt) |
WO (1) | WO2009014524A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022001416A (es) * | 2019-08-02 | 2022-05-26 | Koite Health Oy | Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente. |
CN114053406B (zh) * | 2021-11-23 | 2022-12-09 | 华中科技大学 | 一种多功能光热纳米杀菌材料及制备与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6462070B1 (en) * | 1997-03-06 | 2002-10-08 | The General Hospital Corporation | Photosensitizer conjugates for pathogen targeting |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20020197261A1 (en) * | 2001-04-26 | 2002-12-26 | Chun Li | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
US20030176326A1 (en) * | 2002-03-15 | 2003-09-18 | Ceramoptec Industries Inc. | Photosensitzers for photodynamic therapy of microbial infections |
US20040186087A1 (en) * | 2003-03-20 | 2004-09-23 | Ceramoptec Industries, Inc. | Siderophore conjugates of photoactive dyes for photodynamic therapy |
JP2007521338A (ja) * | 2004-01-07 | 2007-08-02 | アンビット バイオサイエンシス コーポレーション | 共役化された低分子 |
US8153111B2 (en) * | 2004-06-18 | 2012-04-10 | Ceramoptec Industries, Inc. | Photo-triggered release of active substances from dendrimer-photosensitizer complexes |
-
2007
- 2007-07-27 MX MX2009001074A patent/MX2009001074A/es active IP Right Grant
- 2007-07-27 WO PCT/US2007/016951 patent/WO2009014524A2/en active Application Filing
- 2007-07-27 BR BRPI0714667A patent/BRPI0714667A8/pt not_active Application Discontinuation
- 2007-07-27 EP EP07797049.9A patent/EP2049105A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2049105A2 (en) | 2009-04-22 |
WO2009014524A3 (en) | 2020-10-15 |
EP2049105A4 (en) | 2022-03-30 |
WO2009014524A2 (en) | 2009-01-29 |
BRPI0714667A2 (pt) | 2013-08-06 |
MX2009001074A (es) | 2009-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martins et al. | Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities | |
Descourouez et al. | Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents | |
BR112022019557A2 (pt) | Inibidores de replicação de norovírus e coronavírus | |
Howard et al. | Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers | |
Evren et al. | In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin | |
BRPI0410041A (pt) | métodos para tratamento de dor de cabeça de sinusite | |
ES2556243T3 (es) | Agentes terapéuticos que contienen bacteriófagos | |
BR0011116A (pt) | Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas | |
BR112013001577A2 (pt) | conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real | |
BRPI0411016A (pt) | composições antisépticas, processos e sistemas | |
BR0016709A (pt) | Agente antiadesão da flora patogênica da pele | |
BR9711843A (pt) | Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos | |
BR0013010A (pt) | Formulação de cloreto de sódio de moxifloxacina | |
BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
BR112019009953A2 (pt) | substâncias direcionadas a vários órgãos ou tecidos selecionados | |
RU2412710C2 (ru) | Применение тилвалосина в качестве противовирусного агента | |
BR0308316A (pt) | Sais de nateglinida | |
Karau et al. | Exebacase in addition to daptomycin is more active than daptomycin or exebacase alone in methicillin-resistant Staphylococcus aureus osteomyelitis in rats | |
BRPI0916885B8 (pt) | composição farmacêutica | |
BRPI0602397C1 (pt) | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições | |
BRPI0714667A8 (pt) | Conjugado molecular e respectivo uso | |
Palacio et al. | Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy | |
BR0309878A (pt) | Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase | |
Magro-Checa et al. | Septic arthritis due to Cellulosimicrobium cellulans | |
Bliziotis et al. | Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BIOLITEC PHARMA MARKETING LTD. (MY) |
|
B25A | Requested transfer of rights approved |
Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |